Clinical Trials Study
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Aug 6, 2022; 10(22): 7794-7807
Published online Aug 6, 2022. doi: 10.12998/wjcc.v10.i22.7794
Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease
Arndís Finna Ólafsdóttir, Mervi Andelin, Aso Saeed, Sheyda Sofizadeh, Hussein Hamoodi, Per-Anders Jansson, Marcus Lind
Arndís Finna Ólafsdóttir, Mervi Andelin, Sheyda Sofizadeh, Marcus Lind, Department of Medicine, NU-Hospital Group, Uddevalla, Sweden
Arndís Finna Ólafsdóttir, Marcus Lind, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Aso Saeed, Department of Nephrology, Gothenburg University, Sahlgrenska Academy, Institute Internal Medicine, Göteborg, Sweden
Hussein Hamoodi, Statistiska Konsultgruppen, Göteborg, Sweden
Per-Anders Jansson, Wallenberg Laboratory, Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Göteborg, Sweden
Author contributions: Ólafsdóttir AF, Andelin M, and Lind M contributed to the design of this study; Ólafsdóttir AF drafted the manuscript; All authors contributed to the analysis and interpretation of the data, revised the manuscript, and gave final approval of the version to be published.
Institutional review board statement: The protocol was approved by the regional ethical review board of Gothenburg.
Clinical trial registration statement: The trial is registered on clinicaltrial.gov NCT, No. 03378271.
Conflict-of-interest statement: AFO has done consultancy work for Nordic Infucare. SS has done consultancy work for Novo Nordisk, Bayer, Sanofi, and Boehringer Ingelheim ML has received research grants from Ely Lilly and Novonordisk outside the submitted work and personal fees from Astra Zeneca, Boehringer Ingelheim, DexCom, Eli Lilly, MSD and Novonordisk, all outside the current work. AM, AS, HH, and PAJ have no conflict of interest to report.
Data sharing statement: All data are available from the corresponding author (AFO) upon a reasonable request.
CONSORT 2010 statement: The authors have read the CONSORT 2010 statement, and the manuscript was prepared and revised according to the CONSORT 2010 statement.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Arndís Finna Ólafsdóttir, RN, Nurse, Department of Medicine, NU-Hospital Group, Fjällvägen 9, Uddevalla, Sweden. finna.olafsdottir@vgregion.se
Received: January 27, 2022
Peer-review started: January 27, 2022
First decision: March 11, 2022
Revised: April 4, 2022
Accepted: June 3, 2022
Article in press: June 3, 2022
Published online: August 6, 2022
ARTICLE HIGHLIGHTS
Research background

People with diabetes and advanced chronic kidney disease (CKD) often have fluctuating blood glucose levels and today no blood glucose sensors are approved to be used in this patient group.

Research motivation

It is of great importance to give the best possible care to all people with diabetes. This is a patient group with difficult complications due to their diabetes and need all the help they can get.

Research objectives

The objective of this study was to see if the sensors FreeStyle Libre and Dexcom G5 were accurate when used by people with advanced CKD.

Research methods

This was a non-randomized clinical study. The results were evaluated by using mean absolute relative difference as a main analysis. Mean absolute difference and mean difference was also calculated. A surveillance error grid was even used for accuracy evaluations.

Research results

The main analysis found that the Dexcom G5 had a mean absolute relative difference of 15.2% while it was 20.9% for the FreeStyle Libre. There was no significant difference if the patients were on maintenance dialysis or not. There was no significant difference between those with type 1 or 2 diabetes. The surveillance error grid showed that Dexcom G5 had 82% of its values within the safe zone while FreeStyle Libre had 66% within the safe zone.

Research conclusions

The study concludes that the Dexcom G5 produces more accurate values than the FreeStyle Libre.

Research perspectives

This study is a great start for evaluating how we can use glucose sensors for this patient group, but further studies have to be done with more novel glucose sensors.